ATXS vs. PHAT, AVBP, ALT, STOK, KRRO, ANAB, CMPS, CALT, PAHC, and OLMA
Should you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Phathom Pharmaceuticals (PHAT), ArriVent BioPharma (AVBP), Altimmune (ALT), Stoke Therapeutics (STOK), Korro Bio (KRRO), AnaptysBio (ANAB), COMPASS Pathways (CMPS), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical preparations" industry.
Phathom Pharmaceuticals (NASDAQ:PHAT) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.
Phathom Pharmaceuticals has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
Astria Therapeutics received 490 more outperform votes than Phathom Pharmaceuticals when rated by MarketBeat users. Likewise, 72.48% of users gave Astria Therapeutics an outperform vote while only 65.63% of users gave Phathom Pharmaceuticals an outperform vote.
Astria Therapeutics' return on equity of 0.00% beat Phathom Pharmaceuticals' return on equity.
99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are owned by institutional investors. 24.1% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 3.4% of Astria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than Astria Therapeutics. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 6 mentions for Astria Therapeutics. Astria Therapeutics' average media sentiment score of 0.11 beat Phathom Pharmaceuticals' score of -0.20 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.
Astria Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Astria Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Phathom Pharmaceuticals currently has a consensus target price of $21.33, suggesting a potential upside of 134.43%. Astria Therapeutics has a consensus target price of $21.25, suggesting a potential upside of 131.73%. Given Astria Therapeutics' higher probable upside, research analysts clearly believe Phathom Pharmaceuticals is more favorable than Astria Therapeutics.
Summary
Phathom Pharmaceuticals and Astria Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Astria Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Astria Therapeutics Competitors List
Related Companies and Tools
